 |
|
|
| |
Safety, Pharmacokinetics and Antiviral Activity of Novel HBV Capsid Assembly Modulator, JNJ-56136379, in Non-cirrhotic, Treatment-naïve Patients with Chronic Hepatitis B
|
| |
| |
Reported by Jules Levin
EASL 2018 April 11-15 Paris France
F. Zoulim1,2, J.Z. Yogaratnam3, J.J. Vandenbossche4, O. Lenz4, W. Talloen4, C. Vistuer4, I. Moscalu5, A. Streinu-Cercel6, S. Bourgeois7, M. Buti8, J. Crespo9, J.M. Pascasio10, C. Sarrazin11, T. Vanwolleghem12,13, L. Blatt3, J. Fry3
1Croix Rousse Hospital, Hospices Civils de Lyon, France; 2INSERM U1052-Cancer Research Institute of Lyon, France; 3Alios Biopharma (a Janssen Pharmaceutical Company of Johnson & Johnson), USA; 4Janssen Pharmaceuticals BV, Belgium; 5Spitalul Clinic Republican, Moldova; 6National Institute for Infectious Diseases, Carol Davila University of Medicine and Pharmacy, Romania; 7ZNA Jan Palfijn, CPU, Belgium; 8Hospital UniversitarioValld'Hebrón, Spain; 9Hospital Universitario Marques de Valdecilla, Spain; 10Hospital UniversitarioVirgendel Rocio, Spain; 11Medizinische KlinikII, St. Josefs-Hospital, Germany; 12Erasmus MC, University Medical Center, Netherlands; 13Antwerp University Hospital, Belgium
|
| |
|
|
|
|
|
